RESI Conference September 2016 Redefining Early Stage Investments
By Emily MacHale
August 30, 2016
Tustin, CA – Integrium, LLC announced they will be attending the Redefining Early Stage Investments (RESI) Conference on September 13, 2016 in Boston, MA. Integrium has attended numerous RESI Conferences in the past and has been able to develop key relationships through workshops, panels, and group discussions.
Among other companies, Integrium will be able to collaborate with emerging biotechs, medtechs, investors, and more in order to seek partnerships and grow positive outcomes for both parties involved. The conference has opened doors and given Integrium the opportunity to meet with a number of emerging biotech and medical device companies. “I have never seen a better conference for Pre-Clinical – Phase I Biotechs looking to find alternative financing solutions and partners,” mentioned Mike Loftus, Executive Director, Business Development at Integrium, LLC. Guests that attend the RESI Conference range from CEOs looking to gain knowledge on investment trends, startup companies, investors, and various service providers.
RESI enables guests to search for investors, create and maintain relationships, and achieve the main goal of receiving funding along the way. The conference zooms its’ focus on early stage investors via Life Science Nation, such as Family Offices, Venture Philanthropy Funds, Venture Capitalists, Angel Groups, Corporate Venture Capital Funds, and more.
Through a trusted partnership with Proof of Concept Capital, Integrium is able to assist Micro Cap, Small Cap, and Privately held Biotechs looking to raise additional financing, by providing new clinical data to create the next bump in valuation. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases.
To learn more about Integrium Clinical Research, please contact:
Executive Director, Business Development
Phone: (908) 295-4578